Hans Ericsson

2.0k total citations
71 papers, 1.5k citations indexed

About

Hans Ericsson is a scholar working on Pharmacology, Pharmacology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Hans Ericsson has authored 71 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pharmacology, 12 papers in Pharmacology and 12 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Hans Ericsson's work include Pharmacogenetics and Drug Metabolism (12 papers), Antibiotics Pharmacokinetics and Efficacy (9 papers) and Drug Transport and Resistance Mechanisms (7 papers). Hans Ericsson is often cited by papers focused on Pharmacogenetics and Drug Metabolism (12 papers), Antibiotics Pharmacokinetics and Efficacy (9 papers) and Drug Transport and Resistance Mechanisms (7 papers). Hans Ericsson collaborates with scholars based in Sweden, United Kingdom and United States. Hans Ericsson's co-authors include Margareta Nordlander, C G Regårdh, Wilhelm Tham, M.‐L. Danielsson‐Tham, Helle Ericsson Unnerstad, Kevin Wickman, Lars‐Olof Mentzing, Semir Lončarević, Claes F. Högman and Bengt Tholander and has published in prestigious journals such as PLoS ONE, Applied and Environmental Microbiology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Hans Ericsson

66 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hans Ericsson Sweden 23 361 291 275 269 256 71 1.5k
Heinz Schimmel Belgium 27 177 0.5× 682 2.3× 214 0.8× 64 0.2× 159 0.6× 68 2.2k
Franco Pazzucconi Italy 26 228 0.6× 298 1.0× 719 2.6× 38 0.1× 62 0.2× 48 1.7k
Won‐Ki Min South Korea 25 126 0.3× 522 1.8× 317 1.2× 70 0.3× 48 0.2× 176 1.9k
A.P. Jansen Netherlands 20 123 0.3× 411 1.4× 308 1.1× 26 0.1× 69 0.3× 64 1.5k
Michael S. Schwartz United States 22 49 0.1× 327 1.1× 355 1.3× 129 0.5× 34 0.1× 42 1.6k
Christina Khoo United States 28 167 0.5× 680 2.3× 282 1.0× 33 0.1× 380 1.5× 75 2.0k
Ibrahim M. Ibrahim Egypt 27 99 0.3× 1.1k 3.9× 425 1.5× 48 0.2× 62 0.2× 153 3.1k
Wei-Cheng Chen Taiwan 24 106 0.3× 762 2.6× 151 0.5× 37 0.1× 78 0.3× 105 1.8k
Khalid Z. Alshali Saudi Arabia 18 413 1.1× 427 1.5× 224 0.8× 32 0.1× 43 0.2× 42 1.3k
Raúl Beltrán‐Debón Spain 31 208 0.6× 835 2.9× 242 0.9× 21 0.1× 192 0.8× 111 3.1k

Countries citing papers authored by Hans Ericsson

Since Specialization
Citations

This map shows the geographic impact of Hans Ericsson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans Ericsson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans Ericsson more than expected).

Fields of papers citing papers by Hans Ericsson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans Ericsson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans Ericsson. The network helps show where Hans Ericsson may publish in the future.

Co-authorship network of co-authors of Hans Ericsson

This figure shows the co-authorship network connecting the top 25 collaborators of Hans Ericsson. A scholar is included among the top collaborators of Hans Ericsson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans Ericsson. Hans Ericsson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pizzato, Patricia Ely, Maria Heijer, Mikael Sunnåker, et al.. (2024). The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of mitiperstat. British Journal of Clinical Pharmacology. 90(12). 3212–3220. 1 indexed citations
2.
Parkinson, Joanna, Dinko Rekić, Karin Nelander, et al.. (2024). The myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic doses. Pharmacology Research & Perspectives. 12(2). e1184–e1184. 2 indexed citations
3.
Heerspink, Hiddo J.L., et al.. (2023). A Phase IIb Randomized, Double-Blind, Placebo-Controlled, Multi-Centre, Dose Ranging Study of Atuliflapon in Participants with Proteinuric CKD. Journal of the American Society of Nephrology. 34(11S). 677–678. 2 indexed citations
4.
5.
Li, Xueqing, Maria Heijer, Ryan A. Bragg, et al.. (2023). Mass Balance and Absorption, Distribution, Metabolism, and Excretion Properties of Balcinrenone following Oral Administration in Combination with Intravenous Microtracer in Healthy Subjects. Drug Metabolism and Disposition. 51(8). 995–1004. 7 indexed citations
6.
Heerspink, Hiddo J.L., Gordon Law, Konstantina Psachoulia, et al.. (2021). Design of FLAIR: a Phase 2b Study of the 5-Lipoxygenase Activating Protein Inhibitor AZD5718 in Patients With Proteinuric CKD. Kidney International Reports. 6(11). 2803–2810. 8 indexed citations
7.
Pettersen, Daniel, Johan Broddefalk, Hans Emtenäs, et al.. (2019). Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease. Journal of Medicinal Chemistry. 62(9). 4312–4324. 31 indexed citations
8.
9.
Hamrén, Bengt, Hans Ericsson, Ola Samuelsson, & Mats O. Karlsson. (2008). Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function – evidence of interconversion. British Journal of Clinical Pharmacology. 65(6). 855–863. 11 indexed citations
10.
Andersson, Tommy B., et al.. (2004). AN EVALUATION OF THE IN VITRO METABOLISM DATA FOR PREDICTING THE CLEARANCE AND DRUG-DRUG INTERACTION POTENTIAL OF CYP2C9 SUBSTRATES. Drug Metabolism and Disposition. 32(7). 715–721. 56 indexed citations
11.
Nordlander, Margareta, Per‐Ove Sjöquist, Hans Ericsson, & Lars Rydén. (2004). Pharmacodynamic, Pharmacokinetic and Clinical Effects of Clevidipine, an Ultrashort‐Acting Calcium Antagonist for Rapid Blood Pressure Control. Cardiovascular Drug Reviews. 22(3). 227–250. 73 indexed citations
12.
Eriksson, Ulf G., Ulf Bredberg, Kurt‐Jürgen Hoffmann, et al.. (2003). Absorption, Distribution, Metabolism, and Excretion of Ximelagatran, an Oral Direct Thrombin Inhibitor, in Rats, Dogs, and Humans. Drug Metabolism and Disposition. 31(3). 294–305. 125 indexed citations
13.
Wang, Qing‐Dong, Daisuke Segawa, Hans Ericsson, et al.. (2002). Time-dependent Cardioprotection With Calcium Antagonism and Experimental Studies With Clevidipine in Ischemic-reperfused Pig Hearts: Part I. Journal of Cardiovascular Pharmacology. 40(2). 228–234. 25 indexed citations
14.
Vuylsteke, Alain, Q. J. W. Milner, Hans Ericsson, et al.. (2000). Pharmacokinetics and pulmonary extraction of clevidipine, a new vasodilating ultrashort-acting dihydropyridine, during cardiopulmonary bypass †. British Journal of Anaesthesia. 85(5). 683–689. 23 indexed citations
15.
Ericsson, Hans, Bengt Tholander, & C G Regårdh. (1999). In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolised by esterases, in different animal species and man. European Journal of Pharmaceutical Sciences. 8(1). 29–37. 53 indexed citations
16.
Ericsson, Hans, et al.. (1999). Pharmacokinetics and pharmacodynamics of clevidipine in healthy volunteers after intravenous infusion. European Journal of Clinical Pharmacology. 55(1). 61–67. 55 indexed citations
17.
Schwieler, Jonas, et al.. (1999). Circulatory Effects and Pharmacology of Clevidipine, a Novel Ultra Short Acting and Vascular Selective Calcium Antagonist, in Hypertensive Humans. Journal of Cardiovascular Pharmacology. 34(2). 268–274. 32 indexed citations
18.
Ericsson, Hans & Per Stålhandske. (1997). PCR detection of Listeria monocytogenes in ‘gravad’ rainbow trout. International Journal of Food Microbiology. 35(3). 281–285. 13 indexed citations
19.
Nordrum, Ivar S., et al.. (1991). Remote frozen section service: A telepathology project in northern Norway. Human Pathology. 22(6). 514–518. 121 indexed citations
20.
Ericsson, Hans, et al.. (1953). [Determination of chemoresistance of bacteria; principles of technic and evaluation].. PubMed. 50(9). 476–81. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Heinz Schimmel Breakdown of academic impact, for papers by Franco Pazzucconi Breakdown of academic impact, for papers by Won‐Ki Min Breakdown of academic impact, for papers by A.P. Jansen Breakdown of academic impact, for papers by Michael S. Schwartz Breakdown of academic impact, for papers by Christina Khoo Breakdown of academic impact, for papers by Ibrahim M. Ibrahim Breakdown of academic impact, for papers by Wei-Cheng Chen Breakdown of academic impact, for papers by Khalid Z. Alshali Breakdown of academic impact, for papers by Raúl Beltrán‐Debón
Rankless by CCL
2026